Purpose We used systematic review and meta-analysis to identify and assimilate evidence quantifying blindness and visual impairment (VI) associated with myopic macular degeneration (MMD), then derived models to predict global patterns. The models were used to estimate the global prevalence of blindness and VI associated with MMD from 2000 to 2050. Methods The systematic review identified 17 papers with prevalence data for MMD VI fitting our inclusion criteria. Data from six papers with age-specific data were scaled to relative age-dependent risk and meta-analysed at VI and blindness levels. We analysed variance in all MMD VI and blindness data as a proportion of high myopia against variables from the place and year of data collection, with a model based on health expenditure providing the best correlation. We used this model to estimate the prevalence and number of people with MMD VI in each country in each decade. Results We included data from 17 studies comprising 137 514 participants. We estimated 10.0 million people had VI from MMD in 2015 (prevalence 0.13%, 95% CI 5.5 to 23.7 million, 0.07% to 0.34%), 3.3 million of whom were blind (0.04%, 1.8 to 7.8 million, 0.03% to 0.10%). We estimate that by 2050, without changing current interventions, VI from MMD will grow to 55.7 million people (0.57%, 29.0 to 119.7 million, 0.33% to 1.11%), 18.5 million of whom will be blind (0.19%, 9.6 to 39.7 million, 0.11% to 0.37%). Conclusion The burden of MMD blindness and VI will rise significantly without efforts to reduce the development and progression of myopia and improve the management of MMD.
InTRoduCTIon
Uncorrected refractive error is the main cause of presenting visual impairment (VI) globally, and myopia is the most common refractive error. 1 2 Even with refractive correction, those with myopia are at higher risk of a range of conditions, including cataract, glaucoma, retinal pathologies such as tears and detachment, and myopic macular degeneration (MMD). [3] [4] [5] MMD alone has been found to cause 12.1% of VI (approximately 200 000 people) in Japan. 6 The prevalence of myopia and high myopia has been observed to be increasing globally. 2 While this appears most dramatic in young East Asians, it is increasingly observed across other regions and age groups. 2 Trends in lifestyle, education and demographics mean global myopia and high myopia prevalence is projected to continue rising. 2 Estimates of the impact of this trend on the epidemiology of VI from MMD would inform planning for prevention and management of the problem. However, despite many prevalence studies on myopia, there are no estimates of the regional or global prevalence of VI caused by high myopia or MMD, or projected future changes. This paper reviews population-based and blindness registry studies to estimate the global prevalence of VI/blindness associated with MMD, with modelling and projections to 2050. An expanded background and additional references can be found in online supplementary file 1.
MeThodS

Studies, databases and data organisation
We performed a systematic review of the prevalence of VI and blindness associated with MMD, summarised in figure 1. Sixteen papers were included in our analysis of the prevalence of MMD VI/blindness. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] One additional paper was identified as having useful information on the age spread of myopia-related VI. 4 The epidemiology of high myopia was taken from a systematic review and meta-analysis of the prevalence of myopia and high myopia. 2 We searched for alternative models, but no comparable evidence was found.
Country-specific population data for each decade from 2000 through 2050, in 10-year age groups from 0 to 90+, were drawn from the United Nations Department of Economic and Social Affairs. 22 Countries were aggregated into the 21 Global Burden of Disease regions for data presentation. 1
definitions
High myopia was classified as spherical equivalent ≤−5.00 D in line with international agreement. 23 MMD was defined as degenerative changes in the macula, including diffuse or patchy chorioretinal atrophy, lacquer cracks, choroidal neovascularisation and atrophy related to choroidal Global issues Figure 1 Flow diagram summarising the systematic search, using medical subject headings (MeSH) terms, and review process for identifying evidence on the prevalence of MMD VI and/or blindness. Our inclusion criteria were population-based or blindness registry studies quantifying prevalence, with sampling representative of whole communities. Exclusion criteria were unspecified or ambiguous definitions, not specifying the number of eligible participants, participation rate <75%, use of data duplicating other included studies or aggregating MMD VI with other conditions (eg, all macular conditions). MMD, myopic macular degeneration; VI, visual impairment. neovascularisation, in the presence of higher levels of myopia. 24 While MMD can occur in younger eyes with relatively low levels of myopia, it is more likely to occur in older, longer, more myopic eyes. 4 5 Consequently, we translated the epidemiological evidence from population prevalence for a specific age group, year of data collection, country and urbanisation level into proportions of people with high myopia who have MMD VI using matched high myopia data. 2 These proportions enabled more meaningful intercountry comparisons.
We used the WHO definitions of VI (visual acuity worse than 6/18) and blindness (visual acuity worse than 3/60). 25
Meta-analysis and modelling
Six papers provided detailed information on the relationship between age and prevalence of MMD VI and blindness. 4 8 10 13 14 18 Data from these six papers were scaled to relative age-dependent risk in 10-year age groups from 0 to 90+. We used a standard meta-analysis tool (Comprehensive Meta-Analysis (V.3, Biostat, Englewood, New Jersey, USA)) to perform a weighted analysis of the relative risk in each age group. Regression analysis of the meta-analysis results against age found that exponential curves with r 2 of 0.93 and 0.96 best described the relative risk of VI and blindness, respectively:
Relative risk of MMD VI = 0.00002 * exp (0.0756 * (age)) , and Relative risk of MMD blindness = 0.00001 * exp (0.0796 * (age)) .
We applied these age-specific relative risks of VI/blindness associated with MMD to data from all 16 papers in our main analysis, scaled to ensure that the overall VI/blindness associated with MMD remained equivalent to the primary data. We then combined age-specific MMD VI and blindness in 10-year age groups with the prevalence of high myopia data from the same urbanisation level of the same country, decade and age groups, 2 to give the proportion of people with high myopia over 40 years of age who have MMD VI/blindness. Analysis of the proportion data suggested there is some factor beyond the prevalence and age distribution of high myopia that affects not the prevalence of MMD itself but vision outcomes associated with MMD. Suspecting a factor related to country-level detection and management of myopia and consequent ability to prevent vision loss, we analysed the study time-specific and place-specific proportion of people with high myopia who have MMD VI or blindness against variables describing country-level development (full list and sources provided in online supplementary file 1). The following were the best correlations for the proportion of high myopes with MMD VI (r 2 =0.77) and blindness (r 2 =0.85):
VI attributed to MMD = 0.1376 * exp (0.0008 * (HE)) , and Blindness attributed to MMD = 0.0473 * exp (0.0009 * (HE)) ,
where HE=health expenditure per capita in US$.
Figure 2
The age distribution of global blindness associated with myopic macular degeneration (MMD) in 2000 and 2050. Both age-specific global prevalence (top) and the number of people predicted to be blind (bottom) are shown.
The equations are based on primary evidence covering 73% of the global population. We used the equations to calculate the proportion of high myopes who have VI and blindness associated with MMD, using each country's HE when that lay within the envelope of the primary evidence (US$62-US$2835 per capita), or using the closest limit of the envelope for countries with HE outside the envelope. 26 We then combined the country-specific proportions with the prevalence of high myopia for each country, and the meta-analysed 0 to 90+ age distribution of VI and blindness associated with MMD. The resulting country-specific prevalences for each 10-year age group from 0 to 90+ were combined with the population data to estimate the number of people with MMD VI and blindness. Crude and age-standardised all-ages prevalence of VI and blindness associated with MMD was calculated for each Global Burden of Disease region.
Projections for each decade to 2050 were based on the same model. HE was kept constant, so our projections across decades were based on change in high myopia, 2 age demographics and population, 22 and assumed a constant proportion of MMD VI to high myopia ratio.
Confidence intervals
In addition to the 95% confidence limits calculated in the meta-analysis of relative risk between age groups and the 95% confidence limits in high myopia estimates, uncertainty in future population projections was represented by the high and low variant projections from the United Nations. 22 
ReSulTS
A description and summary of findings from the included studies are provided in the text and table S1 of online supplementary file 1. Figure 2A ,B shows our estimated age distribution of global MMD blindness in 2000 and 2050. Prevalence rises exponentially with age in both decades, but is scaled upwards in 2050 due to increasing high myopia and the spread of high myopia from younger groups in 2000 through all ages by 2050. Figure 3A ,B illustrates our global estimates of people with MMD VI and blindness. In 2000, MMD VI was estimated to affect 4.2 million people, that is, 0.07% of the world population (95% CI 2.3 to 9.8 million, 0.04% to 0.16%), increasing to 55.7 million in 2050, that is, 0.57% (29.0 to 119.7 million, 0.33% to 1.11%). MMD blindness in 2000 was estimated to affect 1.3 million people, that is, 0.02% (0.8 to 3.2 million, 0.01% to 0.05%), increasing to 18.5 million in 2050, that is, 0.19% (9.6 to 39.7 million, 0.11% to 0.37%). Table 1 shows the regional differences predicted by our model. In 2000, the all-ages prevalence of MMD VI ranged from 0.011% in Oceania (crude, or 0.019% age-standardised) to 0.025% (crude, or 0.045% age-standardised) in Sub-Saharan Africa, to 0.097% (crude, or 0.111% age-standardised) in Asia (averaged across Central, East, South and South-East Asian regions). All regions were predicted to have an increase in prevalence of VI associated with MMD through to 2050, with Sub-Saharan Africa increasing to 0.179% (crude, or 0.459% age-standardised) and Asia increasing to 0.960% (crude, or 0.871% age-standardised).
Global issues
Additional details are available in online supplementary file 1.
dISCuSSIon
Our evidence-based model predicts significant increases in VI and blindness associated with MMD, with consequent quality of life and socioeconomic impact, and therefore implications for planning comprehensive eye care services globally. Methods to reduce the development of myopia, progression to high myopia and management of MMD are all warranted to reduce expected burden. Analysis of variance across available studies shows an association between VI attributed to MMD and a country's HE. The nature of the relationship is not clear from this analysis. Robust methodology in each primary study attributes VI cause directly to MMD, suggesting a protective effect of HE preventing MMD from progressing to VI. Timely antivascular endothelial growth factor treatment seems the most likely explanation, but this is only known to be useful in a specific complication of MMD, myopic choroidal neovascularisation, 27 and was not in widespread use at the time of many of the primary studies. Thus, we have taken the conservative approach of assuming only an association. It is possible that a related factor-for example, better refractive care leading to people being categorised into different levels of VI-is responsible for the relationship between HE and MMD vision outcomes. Our model refers to 'VI associated with MMD', and we used this location effect at the country level. It is possible that there are also effects of gender, ethnicity and generation, but there are insufficient data to determine the effects other than the level of myopia and location at this stage.
We predict the prevalence of VI associated with MMD will increase eightfold between 2000 and 2050. This dramatic increase is due to the compounding effects of increasing myopia, shifting high myopia demographics towards older age, increasing mean spherical equivalent (and axial length) and the ageing population. In terms of number rather than prevalence, the increase is predicted to be 13 times for VI associated with MMD. In global terms, the 'myopia epidemic' has been a relatively recent phenomenon, most marked in young people. This means that while there is now a high prevalence of high myopia in young people, the impact of high myopia-associated complications will only become evident over the following decades, as these people age and become susceptible to MMD VI.
We have assumed a constant proportion of people with high myopia having MMD VI between 2000 and 2050. This may be conservative because the predicted rise in average spherical equivalent within the high myopia group is likely to increase the risk of VI, 2 4 5 and we have not included the possibility that people with low to moderate myopia can develop MMD VI. 28 Counteracting these factors, successful myopia prevention or control strategies, together with improved detection and treatment of MMD, could reduce the number of people progressing to VI. Additionally, changes in the myopia causation mix over time may lead to different rates of VI from MMD. On balance, we feel our model is based on the evidence as it exists today, and is a reasonable balance of these factors.
Our study design has some potential limitations. The first is the spread of primary evidence around the world-there could be location and ethnicity effects that have not been detected in this analysis. The primary evidence comes from the Asia Pacific High Income, East Asia, Central Europe and Western Europe regions. No study provided evidence that ethnicity would affect susceptibility to VI associated with MMD in eyes of the same age, size, refractive error and country location, although it is possible that differences do exist. We mitigated against errors induced by the representation of regions in the primary evidence by using MMD VI as a proportion of high myopia, which seems likely to be the strongest control variable between populations when meta-analysing and modelling data. The second limitation is that there was only one available peer-reviewed global model of high myopia prevalence, 2 which we used on the understanding that limitations in that paper would be transferred to this work. The third limitation is a lack of primary data differentiating MMD VI into small enough age groups. We used the age spread from the six studies with the best age group differentiation. Fourth, projecting based on current information has the potential to miss variations over time, such as improved myopia control or management of MMD. Fifth, while our modelling suggested that country-level HE is associated with the distribution of MMD VI in 2015, we did not include changes in HE in our future projections. It is hoped that access to and quality of healthcare will increase significantly over the next 30 years. If improvements in access to and quality of healthcare enable improved visual outcomes in MMD over time, our model will overestimate the future problem. Sixth, we assume there are no gender or cohort effects on the susceptibility to VI associated with MMD of an eye of the same age, size, refractive error and country location. We view this as a conservative approach since there is no consistent evidence showing gender and cohort effects on MMD VI at this time.
Strategies to prevent myopia, such as increased time outside or different educational approaches, have the potential to reduce the future prevalence of high myopia and the risk of developing MMD VI. Likewise, strategies to reduce myopia progression, such as low-dose atropine and specific spectacle and contact lens designs, have similar potential. Improved surveillance, access to care, case management and treatment options for avoiding VI associated with MMD could also decrease risk over time. 28 Additional discussion is available in online supplementary file 1.
In conclusion, our systematic review, meta-analysis and modelling of the evidence describing VI and blindness associated with MMD have significant implications for planning comprehensive eye care services globally, including managing and, if possible, preventing the ocular complications and VI that may occur among almost a billion people with high myopia.
